Aarti Drugs (NSE:AARTIDRUGS) EPS (Basic): ₹21.35 (TTM As of Mar. 2026)


NSE:AARTIDRUGS Aarti Drugs Ltd NSE:AARTIDRUGS
75 GF Score
Price ₹375.30
GF Value ₹496.79
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Aarti Drugs EPS (Basic)?

Aarti Drugs NSE:AARTIDRUGS -0.29% 75 EPS (Basic) is ₹21.35 as of Mar. 2026. GuruFocus rates NSE:AARTIDRUGS with a GF Score™ of 75/100 and a GF Value™ of ₹496.79 (Modestly Undervalued). The stock has 3 warning signs investors should review.

Aarti Drugs's basic earnings per share (Basic EPS) for the three months ended in Mar. 2026 was ₹6.05. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹21.35.

Aarti Drugs's EPS (Diluted) for the three months ended in Mar. 2026 was ₹6.05. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 was ₹21.35.

Aarti Drugs's EPS without NRI for the three months ended in Mar. 2026 was ₹6.05. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 21.35.

During the past 12 months, Aarti Drugs's average EPS without NRIGrowth Rate was 16.40% per year. During the past 3 years, the average EPS without NRI Growth Rate was 5.70% per year. During the past 5 years, the average EPS without NRI Growth Rate was -6.30% per year. During the past 10 years, the average EPS without NRI Growth Rate was 11.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 13 years, Aarti Drugs's highest 3-Year average EPS without NRI Growth Rate was 50.60% per year. The lowest was -14.60% per year. And the median was 14.80% per year.

Aarti Drugs  (NSE:AARTIDRUGS) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Aarti Drugs EPS (Basic) Related Terms

Aarti Drugs EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Aarti Drugs's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aarti Drugs EPS (Basic) Chart

Aarti Drugs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
EPS (Basic)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.14 17.97 18.56 18.35 21.36

Aarti Drugs Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.88 5.91 4.95 4.44 6.05
NSE:AARTIDRUGS
75GF Score
Aarti Drugs Ltd NSE:AARTIDRUGS
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aarti Drugs EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Aarti Drugs's Basic EPS for the fiscal year that ended in Mar. 2026 is calculated as

Basic EPS (A: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(1949.2-0)/91.270
=21.36

Aarti Drugs's Basic EPS for the quarter that ended in Mar. 2026 is calculated as

Basic EPS (Q: Mar. 2026 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(551.9-0)/91.270
=6.05

EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹21.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of ₹21.35 mean?
Aarti Drugs (NSE:AARTIDRUGS) has a EPS (Basic) of ₹21.35 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Aarti Drugs and its competitors.
Is Aarti Drugs' EPS (Basic) too high?
Aarti Drugs' current EPS (Basic) is ₹21.35. Overall, Aarti Drugs has a GF Score™ of 75/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Aarti Drugs' EPS (Basic) compare to ZTS?
Aarti Drugs' EPS (Basic) of ₹21.35 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Aarti Drugs and its competitors. Aarti Drugs's current EPS (Basic) is ₹21.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aarti Drugs stock overvalued right now?
Based on GuruFocus' analysis, Aarti Drugs (NSE:AARTIDRUGS) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹496.79, compared to a current price of ₹375.30 — trading 24.5% below its estimated fair value. The current EPS (Basic) is ₹21.35. Aarti Drugs' overall GF Score™ is 75/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Aarti Drugs (NSE:AARTIDRUGS), the current EPS (Basic) is ₹21.35 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Aarti Drugs (NSE:AARTIDRUGS) Overvalued in 2026?

Based on GuruFocus' analysis, Aarti Drugs stock appears to be undervalued. The current stock price of ₹375.30 is trading 24.5% below its estimated GF Value™ of ₹496.79. GuruFocus considers Aarti Drugs to be Modestly Undervalued.

Key valuation signals for NSE:AARTIDRUGS:

  • EPS (Basic): ₹21.35
  • GF Value™: ₹496.79 vs. price of ₹375.30 (24.5% below fair value)
  • GF Score™: 75/100 with 3 warning signs

No single metric tells the full story. See the NSE:AARTIDRUGS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Aarti Drugs Business Description

Other Exchanges 524348:India
Address Road No. 29, Plot Number 109-D, Mahendra Industrial Estate, Ground Floor, Sion (East), Mumbai, MH, IND, 400022
Aarti Drugs Ltd is a pharmaceutical company. It offers active pharmaceutical ingredients (APIs), pharma intermediaries, specialty chemicals, and formulations in a range of therapeutic categories, such as anti-inflammatory, cardioprotectant, antibiotic, antidiabetic, and vitamins among others. The product offerings of the company comprise Aceclofenac, Celecoxib, Moxifloxacin, and others. The firm caters to both domestic and international markets and derives a majority of its revenue from its business in India.
75GF Score

Get the complete analysis for NSE:AARTIDRUGS

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹375.30
Price
₹496.79
GF Value